India Glycols Limited has received a customs duty order from the Additional Commissioner, ACC (Import), NCH, New Delhi, related to its Ennature Bio-Pharma division. The company disclosed this development under Regulation 30 of SEBI Listing Regulations on December 30, 2025.

Customs Duty Order Details

The Additional Commissioner issued an order dated December 18, 2025, which was received by the company on December 29, 2025. The order confirms a significant customs duty demand along with penalties for the Bio-Pharma division.

Nature of Violation

The customs order pertains to the classification of certain goods imported by India Glycols' Ennature Bio-Pharma division during the period from June 2020 to September 2024. The adjudicating authority alleged that the company had short-paid customs duty due to incorrect classification of imported goods.

The company had submitted a detailed reply to the allegations raised in the Show Cause Notice (SCN) issued by the Joint Commissioner of Customs, Air Cargo Complex (Import), Delhi. However, the adjudicating authority did not consider the company's submissions favorably and confirmed the entire duty demand along with applicable interest and penalty.

Financial Impact and Company's Response

India Glycols had proactively deposited the duty demand and interest under protest before the issuance of the Show Cause Notice. The pre-deposit details are as follows:

The adjudicating authority has appropriated this pre-deposited amount towards the confirmed duty demand and interest. The company maintains that based on its assessment and legal counsel's advice, it has a strong case on merits. India Glycols believes the imported goods were appropriately classified under the Customs Tariff Heading (CTH), which was not properly appreciated by the adjudicating authority.

Future Course of Action

The company plans to file an appeal against the customs order. Based on its legal assessment, India Glycols does not reasonably anticipate any material impact on its financial, operational, or other activities from this matter. The company has expressed confidence in its position regarding the proper classification of the imported goods and expects to successfully challenge the order through the appellate process.

Tax Appeal Update

India Glycols Limited has recently received a positive outcome in a tax-related matter. The company has successfully contested a tax demand through an appeal process.

Appeal Details

• Appellate Authority: Income Tax Appellate Tribunal (ITAT)
• Appeal Against: Income Tax Demand
• Amount in Dispute: Rs. 5.06 crore

Favorable Ruling

The Income Tax Appellate Tribunal has ruled in favor of India Glycols Limited, providing relief from the disputed tax demand. This decision represents a positive development for the company's financial position.

Implications

The favorable ruling by ITAT is likely to have the following implications:

1. Financial Relief: The company will not have to pay the disputed amount of Rs. 5.06 crore, preserving its cash reserves.
2. Reduced Tax Liability: The decision may lead to a reduction in the company's overall tax liability for the relevant assessment year.
3. Positive Precedent: This ruling could potentially be beneficial for the company in similar future tax matters.

Investor Considerations

While this development is positive, investors should note that:

• This is a one-time event and may not significantly impact the company's long-term financial performance.
• The focus should remain on the company's core business operations and financial fundamentals.

Investors are advised to consider this information alongside other financial and operational metrics when evaluating India Glycols Limited.

About India Glycols Limited

India Glycols Limited is a leading manufacturer of green technology-based bulk, specialty and performance chemicals, natural gums, spirits, industrial gases, sugar, and nutraceuticals. The company has a strong focus on sustainable and eco-friendly products.

Note: This article is based on the information provided in the LODR filing. Investors are encouraged to conduct their own research and consult financial advisors before making investment decisions.